At Mayo Clinic in Rochester, Minnesota, researchers have just completed one of the most detailed cellular maps of meningioma ever created—and the discovery could fundamentally change how doctors predict which brain tumors will come back. The study, published in Nature Genetics and conducted with scientists at Princess Margaret Cancer Center in Toronto, reveals that it's not just the tumor cells themselves that determine whether a meningioma grows slowly or aggressively: the immune cells surrounding the tumor play a critical role in shaping patient outcomes.
Meningioma is the most common brain tumor in adults, with an estimated 30,000 to 40,000 Americans diagnosed each year. While many of these tumors are benign, others can recur or become life-threatening—yet doctors have lacked reliable tools to predict which patients face that risk. Traditional grading systems have proven inadequate, leaving neurosurgeons and patients in uncertainty after surgery about whether a tumor will return.
The Mayo Clinic team tackled this puzzle by mapping the genetic landscape of individual cells rather than treating tumors as a single unit. Using single-cell sequencing and spatial transcriptomics, researchers examined over 500,000 individual cells across hundreds of tumor samples, generating millions of data points. This allowed them to identify distinct states of immune cells—particularly myeloid cells—and discover that certain immune cell programs are strongly linked to how quickly tumors returned after treatment. Some immune cell states appeared associated with more aggressive disease, while others predicted better outcomes.
"We're seeing that it's not just the tumor cells themselves but the ecosystem around them that influences how these tumors grow and respond to treatment," says Gelareh Zadeh, M.D., Ph.D., a Mayo Clinic neurosurgeon and senior author of the study. The findings suggest that these immune cell signatures could eventually add value to existing tumor grading systems and molecular classification tools—potentially helping doctors identify which patients need aggressive therapy and which ones might be spared from unnecessary treatment.
Perhaps most promising: the research hints that these biological signatures may be detectable through blood-based biomarkers, which would allow doctors to monitor patients over time without subjecting them to repeated surgery. Zadeh envisions a future of personalized meningioma care where molecular and cellular insights guide every clinical decision, from the operating room to long-term follow-up.
The study also points to new therapeutic targets. By understanding how immune cells and tumor cells communicate, researchers have identified pathways that might be disrupted to slow tumor growth or enhance treatment response. The next phase involves validating these findings in larger, multicenter studies and translating the biological discoveries into tools that clinicians can actually use at the bedside.
For the roughly one in 100 people whose meningioma recurs, this research offers genuine hope—not because it promises a cure, but because it moves us closer to precise prediction and personalized precision medicine. In a field where outcomes have long remained frustratingly unpredictable, a detailed cellular map is a landmark.